{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:26:11Z","timestamp":1787761571259,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Asparaginase-based treatment regimen for acute lymphocytic leukemia (ALL) is considered as feasible, but there is still a lack of data. In this study, considering the results of other regimen that were not optimum in previous studies. Here, we aimed to investigate the feasibility of PETHEMA ALL-96 treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective feasibility study that was performed in 2019\u20132021 on 13 patients diagnosed with B-cell ALL. Patients were treated by PETHEMA ALL-96 regimen during induction, consolidation, reinduction, and maintenance phases. Patients were followed for 2 years after initiation of PETHEMA ALL-96 regimen for disease-free survival (DFS) and overall survival (OS) of all patients were evaluated after 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Data of 11 patients were analyzed. Within 28 days after treatments, all patients (100%) had no blasts in the bone marrow that was considered as complete remission (CR). The CR rate was 100% within 6 months and 12 months and 81.8% within 2 years after the treatments. Evaluation of OS, CR, and DFS regarding 6, 12, and 24 months showed 100% for all items after 6 and 12 months. After 24 months, the CR was 90.9%, the OS was 81.8% and the DFS was 90.9%. None of the patients died during the induction phase and during the 12 months study. No side effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The PETHEMA ALL-96 had high feasibility and survival rates with no side effects during the study course. It is believed that PETHEMA ALL-96 regimen has beneficial outcomes in young patients with ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_4_22","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T05:36:29Z","timestamp":1681968989000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia"],"prefix":"10.4103","volume":"28","author":[{"given":"Farzaneh","family":"Ashrafi","sequence":"first","affiliation":[{"name":"Aquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Derakhshandeh","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padideh","family":"Oghab","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"104987","DOI":"10.1016\/j.cmpb.2019.104987","article-title":"Mutual information based hybrid model and deep learning for acute lymphocytic leukemia detection in single cell blood smear images","volume":"179","author":"Jha","year":"2019","journal-title":"Comput Methods Programs Biomed"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ajh.24074","article-title":"Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome","volume":"90","author":"Badar","year":"2015","journal-title":"Am J Hematol"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"e0210515","DOI":"10.1371\/journal.pone.0210515","article-title":"FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation","volume":"14","author":"Steiner","year":"2019","journal-title":"PLoS One"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bspc.2018.01.020","article-title":"Classification of acute leukemia using medical-knowledge-based morphology and CD marker","volume":"44","author":"Laosai","year":"2018","journal-title":"Biomed Signal Process Control"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12940-016-0154-8","article-title":"Air toxics and early childhood acute lymphocytic leukemia in Texas, a population based case control study","volume":"15","author":"Symanski","year":"2016","journal-title":"Environ Health"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"83","DOI":"10.29252\/cjns.4.13.83","article-title":"Effects of estrogen and progesterone on different immune cells related to multiple sclerosis","volume":"4","author":"Rafiee Zadeh","year":"2018","journal-title":"Casp J Neurol Sci"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cam4.1266","article-title":"Second primary acute lymphoblastic leukemia in adults: A SEER analysis of incidence and outcomes","volume":"7","author":"Swaika","year":"2018","journal-title":"Cancer Med"},{"key":"R11-20240830","first-page":"100","article-title":"Serum levels of histamine and diamine oxidase in multiple sclerosis","volume":"7","author":"Rafiee Zadeh","year":"2018","journal-title":"Am J Clin Exp Immunol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","article-title":"New therapeutic strategies in acute lymphocytic leukemia","volume":"12","author":"Man","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/2040620716652289","article-title":"Recent advances and novel treatment paradigms in acute lymphocytic leukemia","volume":"7","author":"Papadantonakis","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","article-title":"Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia","volume":"21","author":"Douer","year":"2016","journal-title":"Oncologist"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with Ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A Single-Centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"key":"R17-20240830","first-page":"58","article-title":"Alcohol and multiple sclerosis: An immune system-based review","volume":"12","author":"Fahim","year":"2020","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"Egler","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.blre.2017.06.002","article-title":"Catalyzing improvements in ALL therapy with asparaginase","volume":"31","author":"Marini","year":"2017","journal-title":"Blood Rev"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2015.12.023","article-title":"L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL","volume":"771","author":"Ali","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.12733","article-title":"Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol","volume":"165","author":"Raja","year":"2014","journal-title":"Br J Haematol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/pon.4488","article-title":"Traumatic stress in patients with acute leukemia: A prospective cohort study","volume":"27","author":"Rodin","year":"2018","journal-title":"Psychooncology"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/cam4.2814","article-title":"A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial","volume":"9","author":"Ribera","year":"2020","journal-title":"Cancer Med"},{"key":"R27-20240830","first-page":"193","article-title":"Evaluating the feasibility of prescribing hyper-CVAD regimen in adult acute lymphoblastic leukemia","volume":"30","author":"Azadbakht","year":"2012","journal-title":"J Isfahan Med Sch"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000492531","article-title":"Comparison between Hyper-CVAD and PETHEMA ALL-93 in adult acute lymphoblastic leukemia: A single-center study","volume":"63","author":"Erkut","year":"2018","journal-title":"Chemotherapy"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_4_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:02:12Z","timestamp":1787760132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_4_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_4_22","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-01-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}